CCL17 Recombinant Monoclonal Antibody

Code: CSB-RA856406MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human, Mouse, Macaca fascicularis

Application: ELISA, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q92583

Target Names

CCL17

Alternative Names

A-152E5.3 antibody; A152E53 antibody; ABCD 2 antibody; ABCD2 antibody; C-C motif chemokine 17 antibody; CC chemokine TARC antibody; CCL17 antibody; CCL17_HUMAN antibody; Chemokine CC Motif Ligand 17 antibody; MGC138271 antibody; MGC138273 antibody; SCYA17 antibody; Small Inducible Cytokine A17 antibody; Small Inducible Cytokine A17 Precursor antibody; Small Inducible Cytokine Subfamily A (Cys Cys) antibody; Small Inducible Cytokine Subfamily A (Cys Cys) Member 17 antibody; Small-inducible cytokine A17 antibody; T Cell Directed CC Chemokine antibody; Thymus and activation regulated chemokine antibody; Thymus and activation-regulated chemokine antibody

Species Reactivity

Human, Mouse, Macaca fascicularis

Immunogen

Recombinant Human CCL17 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG2

Clone No.

7D3

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
ELISA	1:5000-1:50000
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

The Binding Activity of Human CCL17 with Anti-CCL17 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Anti-CCL17 recombinant antibody at 2 μg/mL can bind Human CCL17 protein (CSB-MP856406HU) . The EC₅₀ is 2.403-2.741 ng/mL.
The Binding Activity of Macaca mulatta CCL17 with Anti-CCL17 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Anti-CCL17 recombinant antibody at 2 μg/mL can bind Mouse Ccl17 protein (CSB-MP6512MO). The EC₅₀ is 0.9792-1.486 ng/mL.
The Binding Activity of Macaca mulatta CCL17 with Anti-CCL17 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Anti-CCL17 recombinant antibody at 2 μg/mL can bind Macaca mulatta CCL17 protein (CSB-MP811562MOW). The EC₅₀ is 1.953-2.469 ng/mL.
Overlay Peak curve showing Raji cells stained with CSB-RA856406MA1HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was Fluorescein (FITC) AffiniPure Goat Anti-Human IgG, Fcγ fragment specific at 1:200 dilution for 35 min at 4℃.Control antibody (green line) was human IgG1 (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

CCL17, also known as thymus and activation-regulated chemokine (TARC), plays a central role in immune cell trafficking and inflammatory responses. This CC chemokine signals through CCR4 to recruit Th2 lymphocytes and regulatory T cells to sites of inflammation, making it a critical mediator in allergic diseases, atopic dermatitis, and various immunological disorders. Elevated CCL17 levels serve as valuable biomarkers in conditions ranging from autoimmune diseases to certain malignancies, positioning this target at the intersection of basic immunology research and translational medicine.

This recombinant monoclonal antibody against CCL17, clone 7D3, offers the reproducibility essential for longitudinal studies and multi-site collaborations. Produced using recombinant technology with a defined sequence, this human IgG2 isotype antibody eliminates the lot-to-lot variability that can compromise experimental consistency, ensuring your results remain comparable across extended research programs.

Functional ELISA validation demonstrates robust binding activity across multiple species. The antibody binds human CCL17 with an EC50 of 2.403–2.741 ng/mL, mouse Ccl17 with an EC50 of 0.9792–1.486 ng/mL, and Macaca mulatta CCL17 with an EC50 of 1.953–2.469 ng/mL, providing cross-species reactivity for comparative immunology studies and preclinical research models. Flow cytometry validation using Raji cells confirms reliable intracellular detection, with clear separation from isotype control demonstrated at 1:100 dilution following fixation and permeabilization.

Whether investigating chemokine-mediated immune responses, characterizing inflammatory pathways, or developing therapeutic strategies targeting the CCL17-CCR4 axis, this antibody delivers the specificity and cross-species utility needed to advance your immunology research.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells. Binds to CCR4.

Gene References into Functions

The frequency of the CC genotype in the TARC rs223828 SNP was higher in patients with intractable Graves disease than in patients with Graves disease in remission. PMID:29848886
The expression of CCL17 was decreased in nasal polyp (NP) epithelium compared to the epithelium of normal ethmoid sinus, whereas the expression of CCL22 was not decreased. E-cadherin was differentially distributed between the epithelium of normal ethmoid sinus and NP epithelium. EGFR was also decreased in NPs. PMID:29746583
TARC serum levels were elevated in 78% of sarcoidosis patients and correlated with disease severity. PMID:29598931
Serum TARC level may be a potent marker reflecting better response to IL-17A inhibitors for psoriasis treatment. PMID:29655215
This review presents key clinical studies of Multiple sclerosis together with experimental studies in animals that have demonstrated functional roles of CCR4, CCL17, and CCL22 in experimental autoimmune encephalomyelitis pathogenesis. [review] PMID:29099057
Taken together, our data showed a likely positive feedback mechanism of enhanced IL-6 production in ectopic milieu. The high levels of IL-6 in the peritoneal cavity stimulate the expression of CCL17 in endometrial stromal cells by activating JNK signal pathway, and then, CCL17 further induces CCR4 expression on macrophages, which eventually leads to an increase in IL-6 production via NF-kappaB activation. PMID:28240436
Data suggest that high levels of CCL17 and CCL22 in endometrium in women with endometriosis promote (1) recruitment of Tregs, (2) immunosuppression of Tregs, and (3) angiogenesis in endometrium. (Tregs = regulatory T cells) PMID:28383711
Serum TARC levels correlate well with indicators of systemic inflammation and of disease severity among patients with a drug eruption except SJS/TEN. Serum TARC may be a prognostic biomarker of severity of inflammation in drug eruptions. PMID:28648978
TARC production in HaCaT keratinocytes through the interaction between IL-22 and IL-22Ralpha facilitates T-cell migration in atopic dermatitis caused by house dust mites. PMID:26914146
TARC is a candidate biomarker for PTSD only in males. PMID:28170001
High CCL17 expression is associated with colon cancer cell migration. PMID:28146427
GM-CSF can mediate inflammation and pain by regulating IRF4-induced CCL17 production PMID:27525438
Based on the ADEPT study data set, we report that airway mucosal expression of CCL26 was a robust discriminator of type 2 inflammation from healthy nonatopic subjects. Furthermore, airway mucosal CCL26 expression was best identified by using a panel of clinical biomarkers, including Feno values, bEOS counts, and expression of 2 novel markers, sCCL17 and sCCL26 PMID:28089872
Low CCL17 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with clear cell renal cell carcinoma after nephrectomy. PMID:28178948
IP-10 serum increase or TARC/IP-10 ratio decrease along with abnormal hepatic enzymatic alteration could signify early rejection of the transplanted liver. PMID:28245475
elevated pre-treatment levels of sGal-1, sCD163, sCD30 and TARC can be found in patients with classic Hodgkin lymphoma. However, only plasma TARC accurately reflects disease activity and correlates with clinical treatment response. PMID:27610595
levels elevated in rheumatoid arthritis synovial fluid, due to production by mononuclear cells, particularly CD1c classical dendritic cells PMID:27250804
Serum TARC levels are well correlated with blood eosinophil counts in patients with generalized drug eruptions, indicating that Th2-type immune reactions underlie TARC production. Serum TARC measurements also have potent diagnostic value for DIHS, with high sensitivity and specificity. PMID:27497618
Data suggest that Th1 (IFN-gamma-inducible protein-10 IP-10/CXCL10) and Th2 (thymus and activation regulated chemokine TARC/CCL17) and (macrophage derived chemokine MDC/CCL22) cooperatively play a role in the development of ankylosing spondylitis (AS). PMID:26827189
CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma.Higher levels of intratumoral CCL17 expression are associated with poorer survival of hepatocellular carcinoma patients. PMID:26781124
CCL17 and CCL18 dermal expression is associated with leprosy polarity. PMID:25412496
The SNP rs223895 in TARC/CCL17 gene is associated with the susceptibility to Kawasaki disease. PMID:26182268
Serum CCL17 levels are associated with coronary artery disease and atherosclerosis severity independently of traditional cardiovascular risk factors. PMID:25555269
TARC was correlated with disease status and its monitoring may be able to predict PET positivity after alloSCT, thus potentially allowing an early immune manipulation. PMID:25240818
Serum levels of CCL17 were positively correlated with coronary artery disease. PMID:25062565
increased expression in the thymus of myasthenia gravis patients PMID:24397961
TARC and interleukin-31 may be biomarkers for adult atopic dermatitis PMID:24984931
Serum TARC is a promising biomarker for remission and can be used for accurately monitoring proactive treatment for long-term control. [revew] PMID:24628072
disease activity and response biomarker in alopecia areata PMID:24102731
High CXCL10 levels were detected in acutely infected children regardless of virus pathogen, whereas increased CCL17 production was RSV-specific PMID:25013801
Higher serum concentrations of CCL17 at baseline may be predictive of acute exacerbations in patients with chronic hypersensitivity pneumonitis PMID:23705860
might be potential marker of non-eosinophilic oesophagitis gastrointestinal food allergies PMID:24698291
Serum TARC may represent a suitable biomarker for monitoring of atopic dermatitis severity in daily practice. PMID:25199679
Although TARC and I-TAC may not directly regulate pruritus in atopic dermatitis patients, these chemokines are very sensitive disease markers of AD. PMID:24104601
we found that TARC is an easily measured biomarker that is associated with faster TTR, longer PFS, and possibly longer OS in a population of patients with HL who were treated with panobinostat. PMID:23822537
The serum TARC level is a very sensitive biomarker for monitoring the severity and treatment response in AD PMID:25268342
CCL17 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID:12949249
An association between TARC/CCL17 polymorphisms, susceptibility of Kawasaki disease, and intravenous immunoglobulin responses in Kawasaki disease patients. PMID:23942559
Migration assays were performed to evaluate CCL17-induced colon cancer cell (HT-29) chemotaxis and RhoA protein levels were quantified. PMID:24582560
Ginseng inhibited TARC expression via blockade of NF-kappaB activation in HaCaT cells. PMID:23454147
CCL17-induced, CCR4-dependent release of CGRP by human airway epithelial cells represents a novel inflammatory pathway in patients with asthma and allergic disease. PMID:23731651
These data reveal an elevated serum concentration of Th2-attracting chemokines CCL22 and CCL17 in opsoclonus-myoclonus syndrome. PMID:23340773
Autistic children had significantly higher serum levels of TARC than healthy controls PMID:23782855
Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. PMID:23224400
Data suggest an important role for serum CCL17 level as biomarker of drug resistance/remission induction in Hodgkin lymphoma in response to various combined neoplastic agent protocols. PMID:23225085
increased expression in macrophages from asthmatic patients PMID:22981793
Data show that PD-1, PD-L1, PD-L2, CCL17, and CCL22 mRNA was identified in papillomas. PMID:22322668
Serum concentrations of TARC and CTACK were significantly higher in AD (atopic dermatitis) children than in healthy controls, and correlated with severity of symptoms. PMID:22017510
Baseline plasma thymus and activation-regulated chemokine levels correlate with classical Hodgkin's lymphoma tumor burden and serial levels correlate with response to treatment in patients with classical Hodgkin's lymphoma. PMID:22058214
PI16-positive Treg showed enhanced in vitro migration towards the inflammatory chemokines CCL17 and CCL20, suggesting they can migrate to sites of inflammation PMID:22533972